Sheila M. Fleming

Intravenous ethanol/cocaine self-administration initiates high intake of intravenous ethanol alone.

Should the injured and intact hemispheres be treated differently during the early phases of physical restorative therapy in experimental stroke or parkinsonism?

Experimental focal ischemic injury: behavior-brain interactions and issues of animal handling and housing.

Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons.

Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone.

Variable effects of chronic subcutaneous administration of rotenone on striatal histology.

Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect.

Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein.

An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.

3,4-dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease.

Genetic mouse models of parkinsonism: strengths and limitations.

Behavioral phenotypes and pharmacology in genetic mouse models of Parkinsonism.

Effects of antioxidants on cancer prevention and neuromotor performance in Atm deficient mice.

Abnormal colonic motility in mice overexpressing human wild-type alpha-synuclein.

Olfactory deficits in mice overexpressing human wildtype alpha-synuclein.

Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein.

Secretion of amyloidogenic gelsolin progressively compromises protein homeostasis leading to the intracellular aggregation of proteins.

Behavioral outcome measures for the assessment of sensorimotor function in animal models of movement disorders.

Mice overexpressing corticotropin-releasing factor show brain atrophy and motor dysfunctions.

HCN channelopathy in external globus pallidus neurons in models of Parkinson's disease.

A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions.

Analysis of striatal transcriptome in mice overexpressing human wild-type alpha-synuclein supports synaptic dysfunction and suggests mechanisms of neuroprotection for striatal neurons.

Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease.

Cognitive deficits in a mouse model of pre-manifest Parkinson's disease.

Cranial and related sensorimotor impairments in rodent models of Parkinson's disease.

Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited α-synuclein accumulation and age-dependent sensorimotor deficits.

Impaired baroreflex function in mice overexpressing alpha-synuclein.

Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system.

Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons.

Ribosomal s15: A novel therapeutic target for Parkinson's disease.

A GCase Chaperone Improves Motor Function in a Mouse Model of Synucleinopathy.